FADROZOLE HYDROCHLORIDE HEMIHYDRATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	2C14H13N3.2ClH.H2O
Molecular Weight	537.483
Optical Activity	( + / - )
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of FADROZOLE HYDROCHLORIDE HEMIHYDRATE

SMILES

O.Cl.Cl.N#CC1=CC=C(C=C1)C2CCCC3=CN=CN23.N#CC4=CC=C(C=C4)C5CCCC6=CN=CN56

InChI

InChIKey=RBNOZCGLHXZRLF-UHFFFAOYSA-N

InChI=1S/2C14H13N3.2ClH.H2O/c2*15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14;;;/h2*4-7,9-10,14H,1-3H2;2*1H;1H2

HIDE SMILES / InChI

Molecular Formula	C14H13N3
Molecular Weight	223.2731
Charge	0
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Fadrozole (CGS 16949A) is a tetrahydroimidazole-pyridine derivative is a non-steroidal inhibitor of aromatase. In the third phase of clinical trials it was shown, that this drug has good therapeutic effect as a second-line treatment in postmenopausal women with metastatic breast cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 19A1 39	Inhibitor 8,504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast cancer 432	Primary		Phase III 665	Unknown

C_max

Value	Dose	Analyte	Population
32.3 ng/mL	12 mg single, oral	FADROZOLE plasma	Homo sapiens
27.4 ng/mL	12 mg single, oral	FADROZOLE plasma	Homo sapiens
1.5 ng/mL	0.3 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens
1.5 ng/mL	1 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens
1.5 ng/mL	2 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
336 ng × h/mL	12 mg single, oral	FADROZOLE plasma	Homo sapiens
306 ng × h/mL	12 mg single, oral	FADROZOLE plasma	Homo sapiens
10.7 ng × h/mL	0.3 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens
10.5 ng × h/mL	1 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens
10.7 ng × h/mL	2 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.8 h	12 mg single, oral		FADROZOLE plasma	Homo sapiens
2.5 h	12 mg single, oral		FADROZOLE plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
12 mg single, oral Highest studied dose	healthy, ADULT
2 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT	Disc. AE: Depression, Lethargy...
1 mg 2 times / day multiple, oral Studied dose	unhealthy, ADULT	Disc. AE: Weakness, Dizziness...

Showing 1 to 3 of 3 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Depression	grade 3, 3.6% Disc. AE	2 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT
Lethargy	grade 3, 3.6% Disc. AE	2 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT
Dizziness	0.95% Disc. AE	1 mg 2 times / day multiple, oral Studied dose	unhealthy, ADULT
Weakness	0.95% Disc. AE	1 mg 2 times / day multiple, oral Studied dose	unhealthy, ADULT

Showing 1 to 4 of 4 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Evaluation of the male pubertal onset assay to detect testosterone and steroid biosynthesis inhibitors in CD rats.	2001 Apr	11248141
Sex reversal and aromatase in chicken.	2001 Dec 1	11748621
Sex change in the protandrous black porgy, Acanthopagrus schlegeli: a review in gonadal development, estradiol, estrogen receptor, aromatase activity and gonadotropin.	2001 Dec 1	11748620
[Endometriosis and aromatase inhibitor].	2001 Jan	11235156
Brain aromatase is neuroprotective.	2001 Jun 15	11351342

Showing 1 to 5 of 21 entries

Previous1 2 3 4 5Next

Patents

Sample Use Guides

In Vivo Use Guide

0.5, 1.0 or 2.0 mg orally b.d.

Route of Administration: Oral

In Vitro Use Guide

CGS-16949A (fadrozole) blocked aromatase by 50% in human breast cancer homogenates, live breast cancer cells, human placental microsomes and porcine ovarian microsomes at concentrations of 0.008 to 0.02 microM

Substance Class	Chemical
Record UNII	O5207G4XQ9
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

FADROZOLE HYDROCHLORIDE HYDRATE

Preferred Name

English

FADROZOLE HYDROCHLORIDE HEMIHYDRATE

Common Name

English

BENZONITRILE, 4-(5,6,7,8-TETRAHYDROIMIDAZO(1,5-A)PYRIDIN-5-YL)-, HYDROCHLORIDE, HYDRATE (2:2:1)

Systematic Name

English

BENZONITRILE, 4-(5,6,7,8-TETRAHYDROIMIDAZO(1,5-A)PYRIDIN-5-YL)-, MONOHYDROCHLORIDE, HYDRATE (2:1)

Common Name

English

FADROZOLE HYDROCHLORIDE HYDRATE [JAN]

Common Name

English

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

PUBCHEM

11954367

PRIMARY

SMS_ID

100000127581

PRIMARY

FDA UNII

O5207G4XQ9

PRIMARY

EVMPD

SUB33655

PRIMARY

CAS

176702-70-8

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					H0Q44H4ECQ

FADROZOLE HYDROCHLORIDE

ANHYDROUS->SOLVATE


					H0Q44H4ECQ

FADROZOLE HYDROCHLORIDE

PARENT -> SALT/SOLVATE


					H3988M64PU

FADROZOLE

PARENT -> SALT/SOLVATE

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Related Record

Type

Details


					H3988M64PU

FADROZOLE

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Doses

AEs

PubMed

Patents

Sample Use Guides

C_max

T_1/2